Skip to main content
Top
Published in: Pathology & Oncology Research 3/2012

Open Access 01-07-2012 | Research

Expression of GLUT1 and GLUT3 Glucose Transporters in Endometrial and Breast Cancers

Authors: Anna Krzeslak, Katarzyna Wojcik-Krowiranda, Ewa Forma, Paweł Jozwiak, Hanna Romanowicz, Andrzej Bienkiewicz, Magdalena Brys

Published in: Pathology & Oncology Research | Issue 3/2012

Login to get access

Abstract

Cancer cells have accelerated metabolism and high glucose requirements. The up-regulation of specific glucose transporters may represent a key mechanism by which malignant cells may achieve increased glucose uptake to support the high rate of glycolysis. In present study we analyzed the mRNA and protein expression of GLUT1 and GLUT3 glucose transporters by quantitative real-time polymerase chain reaction (Q-PCR) and Western blotting technique in 76 cases of endometrial carcinoma and 70 cases of breast carcinoma. SLC2A1 and SLCA2A3 mRNAs expression was found, respectively in 100% and 97.4% samples of endometrial cancers and only in 50% and 40% samples of breast cancers. In endometrial cancers GLUT1 and GLUT3 protein expression was identified in 67.1% and 30.3% of cases. Analogously, in breast cancers in 48.7% and 21% of samples, respectively. The results showed that both endometrial and breast poorly differentiated tumors (grade 2 and 3) had significantly higher GLUT1 and GLUT3 expression than well-differentiated tumors (grade 1). Statistically significant association was found between SLCA2A3 mRNA expression and estrogen and progesterone receptors status in breast cancers. GLUT1 has been reported to be involved in the uptake of glucose by endometrial and breast carcinoma cells earlier and the present study determined that GLUT3 expression is also involved. GLUT1 and GLUT3 seem to be important markers in endometrial and breast tumors differentiation.
Literature
1.
go back to reference Young CD, Anderson SM (2008) Sugar and fat—that’s where it’s at: metabolic changes in tumors. Breast Cancer Res 10:202PubMedCrossRef Young CD, Anderson SM (2008) Sugar and fat—that’s where it’s at: metabolic changes in tumors. Breast Cancer Res 10:202PubMedCrossRef
2.
go back to reference Ganapathy V, Thangaraju M, Prasad PD (2009) Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 121:29–40PubMedCrossRef Ganapathy V, Thangaraju M, Prasad PD (2009) Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther 121:29–40PubMedCrossRef
3.
go back to reference Warburg O (1930) The metabolizm of tumors. Constable, London Warburg O (1930) The metabolizm of tumors. Constable, London
5.
go back to reference Thorens B, Mueckler M (2010) Glucose transporters in the 21st Century. Am J Physiol Endocrinol Metab 298:E141–E145PubMedCrossRef Thorens B, Mueckler M (2010) Glucose transporters in the 21st Century. Am J Physiol Endocrinol Metab 298:E141–E145PubMedCrossRef
6.
go back to reference Macheda ML, Rogers S, Best JD (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202:654–662PubMedCrossRef Macheda ML, Rogers S, Best JD (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202:654–662PubMedCrossRef
7.
go back to reference Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT (1997) Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 80:1046–1051PubMedCrossRef Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT (1997) Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 80:1046–1051PubMedCrossRef
8.
go back to reference Kawamura T, Kusakabe T, Sugino T et al (2001) Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 92:634–641PubMedCrossRef Kawamura T, Kusakabe T, Sugino T et al (2001) Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 92:634–641PubMedCrossRef
9.
go back to reference Haber RS, Rathan A, Weiser KR et al (1998) GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 83:34–40PubMedCrossRef Haber RS, Rathan A, Weiser KR et al (1998) GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 83:34–40PubMedCrossRef
10.
go back to reference Sakashita M, Aoyama N, Minami R et al (2001) Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. Eur J Cancer 37:204–209PubMedCrossRef Sakashita M, Aoyama N, Minami R et al (2001) Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. Eur J Cancer 37:204–209PubMedCrossRef
11.
go back to reference Kalir T, Wang BY, Goldfischer M et al (2002) Immunohistochemical staining of GLUT1 in benign, borderline and malignant ovarian epithelia. Cancer 94:1078–1082PubMedCrossRef Kalir T, Wang BY, Goldfischer M et al (2002) Immunohistochemical staining of GLUT1 in benign, borderline and malignant ovarian epithelia. Cancer 94:1078–1082PubMedCrossRef
12.
go back to reference Boado RJ, Black KL, Pardridge WM (1994) Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. Mol Brain Res 27:51–57PubMedCrossRef Boado RJ, Black KL, Pardridge WM (1994) Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. Mol Brain Res 27:51–57PubMedCrossRef
13.
go back to reference Estilo CL, O-charoenrat P, Talbot S et al (2009) Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC Cancer 9:11PubMedCrossRef Estilo CL, O-charoenrat P, Talbot S et al (2009) Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC Cancer 9:11PubMedCrossRef
14.
go back to reference Ayala FR, Rocha RM, Carvalho KC et al (2010) GLUT3 as potential prognostic markers for oral squamous cell carcinoma. Molecules 15:2374–2387PubMedCrossRef Ayala FR, Rocha RM, Carvalho KC et al (2010) GLUT3 as potential prognostic markers for oral squamous cell carcinoma. Molecules 15:2374–2387PubMedCrossRef
15.
go back to reference Baer S, Casaubon L, Schwartz MR, Marcogliese A, Younes M (2002) Glut3 expression in biopsy specimens of laryngeal carcinoma is associated with poor survival. Laryngoscope 112:393–396PubMedCrossRef Baer S, Casaubon L, Schwartz MR, Marcogliese A, Younes M (2002) Glut3 expression in biopsy specimens of laryngeal carcinoma is associated with poor survival. Laryngoscope 112:393–396PubMedCrossRef
16.
go back to reference Matsuzu K, Segade F, Matsuzu U et al (2004) Differential expression of glucose transporters in normal and pathological thyroid tissue. Thyroid 14:806–812PubMedCrossRef Matsuzu K, Segade F, Matsuzu U et al (2004) Differential expression of glucose transporters in normal and pathological thyroid tissue. Thyroid 14:806–812PubMedCrossRef
17.
go back to reference Tsukioka M, Matsumoto Y, Noriyuki M et al (2007) Expression of glucose transporters in epithelial ovarian carcinoma: correlation with clinical characteristics and tumor angiogenesis. Oncol Rep 8:361–367 Tsukioka M, Matsumoto Y, Noriyuki M et al (2007) Expression of glucose transporters in epithelial ovarian carcinoma: correlation with clinical characteristics and tumor angiogenesis. Oncol Rep 8:361–367
18.
go back to reference Rudlowski C, Moser M, Becker AJ et al (2004) GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer. Oncology 66:404–410PubMedCrossRef Rudlowski C, Moser M, Becker AJ et al (2004) GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer. Oncology 66:404–410PubMedCrossRef
19.
go back to reference Tavassoli FA, Devilee P (2003) World Health Organization classification of tumours. Pathology & genetics of tumours of the breast and female genital organs, vol 1. IARC, Lyon, pp 217–232 Tavassoli FA, Devilee P (2003) World Health Organization classification of tumours. Pathology & genetics of tumours of the breast and female genital organs, vol 1. IARC, Lyon, pp 217–232
20.
go back to reference Goldman NA, Katz EB, Glenn AS et al (2006) GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol 19:1429–1436PubMed Goldman NA, Katz EB, Glenn AS et al (2006) GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol 19:1429–1436PubMed
21.
go back to reference Wang BY, Kalir T, Sabo E et al (2000) Immunohistochemical staining of GLUT1 in benign, hyperplastic, and malignant endometrial epithelia. Cancer 88:2774–2781PubMedCrossRef Wang BY, Kalir T, Sabo E et al (2000) Immunohistochemical staining of GLUT1 in benign, hyperplastic, and malignant endometrial epithelia. Cancer 88:2774–2781PubMedCrossRef
22.
go back to reference Younes M, Brown RW, Mody DR, Fernandez L, Laucirica R (1995) GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res 15:2895–2898PubMed Younes M, Brown RW, Mody DR, Fernandez L, Laucirica R (1995) GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res 15:2895–2898PubMed
23.
go back to reference Kang SS, Chun YK, Hur MH et al (2002) Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res 93:1123–1128PubMedCrossRef Kang SS, Chun YK, Hur MH et al (2002) Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res 93:1123–1128PubMedCrossRef
24.
go back to reference Schmidt M, Voelker HU, Kapp M et al (2010) Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and down-regulation of M2PK. J Cancer Res Clin Oncol 36:219–225CrossRef Schmidt M, Voelker HU, Kapp M et al (2010) Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and down-regulation of M2PK. J Cancer Res Clin Oncol 36:219–225CrossRef
25.
go back to reference Ravazoula P, Batistatou A, Aletra C et al (2003) Immunohistochemical expression of glucose transporter Glut1 and cyclin D1 in breast carcinomas with negative lymph nodes. Eur J Gynaecol Oncol 24:544–546PubMed Ravazoula P, Batistatou A, Aletra C et al (2003) Immunohistochemical expression of glucose transporter Glut1 and cyclin D1 in breast carcinomas with negative lymph nodes. Eur J Gynaecol Oncol 24:544–546PubMed
26.
go back to reference Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J (1997) Immunohistochemical detection of Glut3 in human tumors and normal tissues. Anticancer Res 17:2747–2750PubMed Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J (1997) Immunohistochemical detection of Glut3 in human tumors and normal tissues. Anticancer Res 17:2747–2750PubMed
27.
go back to reference Godoy A, Ulloa V, Rodríguez F et al (2006) Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol 207:614–627PubMedCrossRef Godoy A, Ulloa V, Rodríguez F et al (2006) Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol 207:614–627PubMedCrossRef
28.
go back to reference Rivenzon-Segal D, Boldin-Adamsky S, Seger D, Seger R, Degani H (2003) Glycolysis and glucose transporter 1 as markers of response to hormonal therapy in breast cancer. Int J Cancer 107:177–182PubMedCrossRef Rivenzon-Segal D, Boldin-Adamsky S, Seger D, Seger R, Degani H (2003) Glycolysis and glucose transporter 1 as markers of response to hormonal therapy in breast cancer. Int J Cancer 107:177–182PubMedCrossRef
Metadata
Title
Expression of GLUT1 and GLUT3 Glucose Transporters in Endometrial and Breast Cancers
Authors
Anna Krzeslak
Katarzyna Wojcik-Krowiranda
Ewa Forma
Paweł Jozwiak
Hanna Romanowicz
Andrzej Bienkiewicz
Magdalena Brys
Publication date
01-07-2012
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2012
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-012-9500-5

Other articles of this Issue 3/2012

Pathology & Oncology Research 3/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine